Valproic acid
Valproic Acid (valproic acid) is a small molecule pharmaceutical. Valproic acid was first approved as Depakene on 1982-01-01. It is used to treat absence epilepsy, alzheimer disease, bipolar disorder, complex partial epilepsy, and epilepsy amongst others in the USA. It is known to target histone deacetylase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Valproate, Valproic acid (discontinued: Depacon, Depakene, Stavzor, Valproic acid)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Valproic acid
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| depakote | New Drug Application | 2025-05-09 |
| depakote er | 2008-04-07 | |
| valproate | ANDA | 2012-08-31 |
| valproate sodium | ANDA | 2025-01-28 |
| valproic | ANDA | 2025-05-23 |
| valproic acid | ANDA | 2025-10-01 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
439 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 9 | 14 | 43 | 38 | 14 | 112 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 10 | 7 | 8 | 22 | 25 | 69 |
| Healthy volunteers/patients | — | — | — | 18 | — | — | 3 | — | 21 |
| Seizures | D012640 | — | G40.4 | 2 | 1 | 6 | 5 | 6 | 19 |
| Depression | D003863 | — | F33.9 | 2 | 4 | 6 | 5 | 2 | 18 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 3 | 1 | 3 | 5 | 5 | 17 |
| Mania | D000087122 | — | F30 | — | 1 | 9 | 5 | 1 | 16 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 4 | 5 | 3 | 1 | 13 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 6 | 5 | — | 12 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 4 | 3 | 2 | 2 | 10 |
Show 75 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 13 | 1 | — | — | 13 |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | 2 | 3 | — | 6 | 11 |
| Glioblastoma | D005909 | EFO_0000515 | — | 3 | 5 | 1 | — | — | 8 |
| Muscular atrophy | D009133 | — | — | 2 | 3 | 1 | — | 1 | 6 |
| Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | 2 | 3 | 1 | — | 1 | 6 |
| Atrophy | D001284 | — | — | 2 | 3 | 1 | — | 1 | 6 |
| Astrocytoma | D001254 | EFO_0000271 | — | 2 | 3 | 1 | — | — | 5 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 1 | 1 | — | 1 | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | — | 1 | — | — | 3 |
| Diffuse intrinsic pontine glioma | D000080443 | — | — | — | 2 | 1 | — | — | 3 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 6 | 12 | — | — | 1 | 16 |
| Neoplasms | D009369 | — | C80 | 14 | 2 | — | — | — | 15 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 12 | — | — | — | 13 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 10 | — | — | — | 11 |
| Preleukemia | D011289 | — | — | 1 | 11 | — | — | — | 11 |
| Myeloid leukemia | D007951 | — | C92 | 2 | 8 | — | — | — | 9 |
| Recurrence | D012008 | — | — | 3 | 2 | — | — | — | 5 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 3 | — | — | — | 5 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 2 | — | — | 1 | 5 |
| Lymphoid leukemia | D007945 | — | C91 | 3 | 2 | — | — | 1 | 5 |
Show 85 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 4 | — | — | — | 1 | 5 |
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 3 | — | — | — | — | 3 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 2 | — | — | — | — | 2 |
| Nasopharyngeal neoplasms | D009303 | — | — | 2 | — | — | — | — | 2 |
| Nervous system neoplasms | D009423 | — | — | 2 | — | — | — | — | 2 |
| Hemorrhagic shock | D012771 | — | — | 2 | — | — | — | — | 2 |
| Personality disorders | D010554 | — | F60.6 | 1 | — | — | — | 1 | 2 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | — | — | — | — | 1 |
Show 29 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 2 | 2 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 1 | 1 |
| Financial stress | D000086522 | — | — | — | — | — | — | 1 | 1 |
| Photophobia | D020795 | — | H53.14 | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | — | — | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Addictive behavior | D016739 | EFO_0004347 | — | — | — | — | — | 1 | 1 |
| Compulsive sexual behavior disorder | D000096583 | — | — | — | — | — | — | 1 | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Valproic acid |
| INN | valproic acid |
| Description | Valproic acid is a branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem. It has a role as an anticonvulsant, a GABA agent, an EC 3.5.1.98 (histone deacetylase) inhibitor, a teratogenic agent, a psychotropic drug, a neuroprotective agent and an antimanic drug. It is a branched-chain saturated fatty acid and a branched-chain fatty acid. It is functionally related to a valeric acid. It is a conjugate acid of a valproate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCC(CCC)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 99-66-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL109 |
| ChEBI ID | 39867 |
| PubChem CID | 3121 |
| DrugBank | DB00313 |
| UNII ID | 614OI1Z5WI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HDAC1
HDAC1
Variants
No data
Financial
Revenue by drug
$
€
ÂŁ
â‚Ł
No data
Estimated US medical usage
Valproic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 61,771 documents
View more details
Safety
Black-box Warning
Black-box warning for: Depakote, Depakote er, Valproate, Valproate sodium, Valproic, Valproic acid
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
68,071 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use